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Abstract 
A previous meta-analysis suggested that the treatment with erdosteine was 
associated with significant amelioration of the cumulative global efficacy index and 
symptoms in comparison to placebo or other mucolytics. However, this conclusion 
was criticized because the meta-analysis, as it had been done, made it impossible to 
preclude the potential operation of selection biases within and across trials, and 
identify any realised benefits of an individual patient data approach. Taking into 
consideration these criticisms and also the publication of two further recent articles 
focused on the prevention of chronic obstructive pulmonary disease (COPD) 
exacerbations with erdosteine, we have carried out a quantitative synthesis via meta-
analysis of the currently available data on the use of this drug. Our findings included 
data from ten studies involving 1,278 patients and show that erdosteine is able to 
improve the clinical score of patients with chronic bronchitis and COPD, and also 
reduces the overall risk of chronic bronchitis/COPD exacerbations, and reduces the 
risk of experiencing at least one exacerbation. Furthermore, our data suggest that 
erdosteine can lengthen the time to the first COPD exacerbation, reduce the duration 
of a COPD exacerbation and the risk of hospitalization from COPD. The documented 
effect of erdosteine in preventing and/or influencing COPD exacerbations is 
important because it indicates that erdosteine can be added to the list of drugs that 
can be recommended for treating COPD. 
Key words 
Erdosteine; chronic bronchitis; COPD; exacerbation; meta-analysis. 
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Introduction 
Mucoactive agents, mucolytics and/or mucoregulators, have two main targets, 
namely to decrease the mucus hypersecretion and alterations in the 
oxidant/antioxidant balance in respiratory diseases such chronic bronchitis and 
COPD [1].  
Making mucus easier to expectorate would seem a sensible goal in the treatment of 
COPD because it has been shown that mucus hypersecretion is associated with 
greater susceptibility to develop COPD, an accelerated annual decline in forced 
expiratory volume in 1 s (FEV1), hospitalisations and excess mortality [2]. However, 
also oxidative stress is an important feature of chronic bronchitis and COPD [3] and 
therefore targeting oxidative stress or boosting the endogenous levels of antioxidants 
is likely to be beneficial as an additional pharmacological approach to the treatment 
of COPD patients [3].  
Many mucolytic agents, such as N-acetyl-L-cysteine, N-acystelyn, erdosteine, 
fudosteine, ergothioneine, and carbocysteine lysine salt, belong to the cysteine family 
of drugs are also known to possess potentially important antioxidant properties [4]. 
Erdosteine [N-(carboxymethylthioacetyl)-homocysteine thiolactone] is a drug 
originally developed as mucolytic agent which is used in many Countries since 1995 
as a treatment of chronic bronchitis and COPD [5]. Erdosteine acts by breaking the 
disulfide bonds of mucus glycoproteins, affecting the physical properties of the 
mucus, thus leading to increased mucus clearance [5]. It also acts as an antioxidant 
through free radical scavenging [6]. Furthermore, erdosteine elicits an anti-
inflammatory activity documented by a significant reduction in the levels of pro-
inflammatory eicosanoids and cytokines in the blood of COPD patients [7] and in the 
release of inflammatory mediators due to the exercise-induced oxidative stress in 
severe COPD patients [8]. Importantly, erdosteine also has antibacterial effects 
through reducing bacterial adhesiveness [9].  
In 2010, some of us performed a meta-analysis to test the available evidence that 
erdosteine treatment in patients with chronic bronchitis/COPD might be effective and 
accompanied by clinically relevant improvements [10]. Fifteen trials (1,046 patients) 
were included in the analysis. Treatment with erdosteine was associated with a 
significant amelioration of the cumulative global efficacy index and symptoms in 
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comparison to placebo or treatment with other mucolytics, but we concluded that 
larger long-term studies with fully validated endpoints were required.  
The Centre for Reviews and Dissemination (CRD), an international center engaged 
exclusively in evidence synthesis in the health field, determined that this meta-
analysis met the Database of Abstracts of Reviews of Effects (DARE) scientific 
quality criteria for a systematic review [11]. However, in their comments, they 
highlighted that the article did not present a flow diagram of article inclusion and 
exclusion. All of the included studies were supplied by the manufacturers, which 
made evaluation of potential bias difficult. They also pointed out that we did not 
report how individual patient data were used to standardise definitions of outcomes 
and subgroups, generate effects across trials in a consistent manner, and verify the 
validity of the raw data. Individual patient covariates were not included in subgroup 
analyses and trial level covariates were not subject to interaction tests. It was, 
therefore, impossible to preclude the potential operation of selection biases within 
and across trials, and identify any realised benefits of an individual patient data 
approach. Additional uncertainty came from high heterogeneity within results and a 
lack of clear definition of clinical significance. 
In light of these criticisms and the recent publication of two further articles focused on 
the prevention of acute exacerbations of COPD with erdosteine [12, 13], we have 
carried out a quantitative synthesis via meta-analysis of the currently available data 
with this drug in order to provide consistent and homogeneous findings that may help 
better clarify the real impact of erdosteine in improving the clinical score of patients 
with chronic bronchitis and/or COPD, and the use of this drug in preventing chronic 
bronchitis/COPD exacerbations. 
Methods 
Search strategy  
This meta-analysis has been registered in PROSPERO (registration number: 
CRD42017068372), and performed in agreement with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) Statement (Figure 1) [14]. 
Furthermore, this synthesis satisfied all the recommended items reported by the 
PRISMA-P 2015 checklist [15].  
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We undertook a comprehensive literature search for studies evaluating the impact of 
erdosteine on chronic bronchitis and/or COPD. In particular, the term "erdosteine” 
was searched for the active treatment, and the terms “chronic bronchitis” OR “chronic 
obstructive pulmonary disease” OR “COPD” were searched for the diseases. The 
search was performed in PubMed, Scopus, Embase, Google Scholar and the 
repository database clinicaltrials.gov [16] to provide relevant studies published up to 
July 31, 2017. No language restriction was applied. Citations of previously published 
meta-analyses and relevant reviews were examined to identify further pertinent 
studies, if any [5, 9, 10, 17-19]. 
Study selection 
Studies reporting the effect of erdosteine vs. placebo/control/baseline in patients with 
chronic bronchitis and/or COPD have been selected. All studies assessing the impact 
of erdosteine on clinical score(s) and the rate of exacerbations of chronic bronchitis 
and/or COPD have been included in the analysis. No restriction on the duration of the 
treatment was applied.  
Two reviewers independently checked the relevant studies identified from the 
literature searches and databases. Studies were selected in agreement with the 
previously mentioned criteria, and any difference in opinion about eligibility was 
resolved by consensus. 
Data extraction 
Data from included studies were extracted and checked for study characteristics and 
duration, doses of medication, patient characteristics, age, gender, smoking habits, 
FEV1, Jadad score, clinical score, and exacerbation and hospitalization rates. 
Endpoints 
The primary endpoint of this quantitative synthesis was the impact of erdosteine on 
the clinical score of patients with chronic bronchitis and/or COPD, and the rate of 
exacerbations, compared to control values in placebo/control groups, or at baseline. 
The secondary endpoint was the influence of erdosteine on the duration of 
exacerbation and rate of hospitalization. 
Quality score, risk of bias and evidence profile 
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The Jadad score, with a scale of 1 to 5 (score of 5 being the best quality), was used 
to assess the quality of the randomized clinical trials (RCTs) concerning the 
likelihood of biases related to randomization, double blinding, withdrawals and 
dropouts [20]. Two reviewers independently assessed the quality of individual 
studies, and any difference in opinion about the quality score was resolved by 
consensus. 
The risk of publication bias was assessed by applying the funnel plot and Egger’s 
test through the following regression equation: SND = a + b × precision, where SND 
represents the standard normal deviation (treatment effect divided by its standard 
error [SE]), and precision represents the reciprocal of the standard error. Evidence of 
asymmetry from Egger’s test was considered to be significant at P<0.1, and the 
graphical representation of 90% confidence bands are presented as described 
elsewhere [20]. 
The optimal information size (OIS) was calculated as previously reported [21, 22], 
and the quality of the evidence assessed in agreement with the Grading of 
Recommendations Assessment, Development, and Evaluation (GRADE) system 
[23]. The risk of publication bias and GRADE analysis were performed on the effect 
estimates resulting from at least 3 high-quality studies (Jadad ≥3). 
Data synthesis and analysis 
Results of this pair-wise meta-analysis are expressed as Standardized Mean 
Difference (SMD), Relative Risk (RR), Natural Logarithmic transformed Proportion 
(Log Proportion, PLN) and 95% confidence interval (95%CI). 
The changes in clinical score are reported as SMD since this outcome was not 
always standardized among the studies (i.e. cumulative Global Efficacy Index [cGEI], 
breathlessness–sputum–cough scale [BCS], Subject’s Global Assessment of 
Disease Severity [SGADS], Physician’s Global Assessment of Disease Severity 
[PGADS], and non-specific clinical score [NSCS]). The risk of COPD exacerbation 
and hospitalization are reported as RR, and normalized as a function of person-
season, where one season includes 3 months [24]. The time to first exacerbation and 
the duration of exacerbation are reported as PLN. Moderate to high levels of 
heterogeneity were considered for I2≥50% [16]. 
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Since data were selected from a series of studies performed by researchers 
operating independently, and a common effect size cannot be assumed, the random-
effects model was used in order to balance the study weights and to adequately 
estimate the 95%CI of the mean distribution of the effect of the active medication on 
the investigated variables [24]. 
Subset analyses were performed by excluding the low-quality studies characterized 
by Jadad score <3, and considering specifically patients affected by chronic 
bronchitis and/or COPD. 
OpenMetaAnalyst [25] software was used for performing the meta-analysis, 
GraphPad Prism (CA, US) software to graph the data, and GRADEpro to evaluate 
the quality of evidence [23]. The statistical significance was assessed for P<0.05. 
Results 
Studies characteristics  
Results obtained from 1,278 patients (52.66% in the active treatment group, 47.34 in 
the control group) were selected from 10 published studies, including 6 studies on 
chronic bronchitis [26-31], 3 studies on COPD [12, 13, 32], and 1 study on patients 
suffering from both chronic bronchitis and COPD [33]. Eight studies had a Jadad 
score ≥3 [12, 13, 26-29, 31, 32], and 2 studies had a Jadad score <3 [30, 33]. The 
studies have been published between 1988 and 2017, and the average duration of 
the studies was 14.02 weeks. Relevant patient demographics, baselines, study 
characteristics, treatments, definitions of exacerbation and Jadad score are 
summarized in Table 1. 
Quantitative synthesis 
Erdosteine elicited a beneficial impact on all the primary endpoints of this meta-
analysis. Treatment with erdosteine significantly (P<0.001) improved the clinical 
score of patients affected by COPD and/or chronic bronchitis vs. control (Figure 2A), 
with no differences (P>0.05) compared to the subset analysis performed by including 
in the synthesis exclusively high-quality studies (SMD -0.44, 95%CI -0.70 – -0.18; I2 
80%, P<0.001). A further specific analysis (Figure 2B) indicated that erdosteine 
significantly (P<0.01 to P<0.001) improved the clinical condition in both COPD 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 8
patients (SMD: all studies -0.56, 95%CI -0.94 – -0.17, I2 85%, P<0.001; high-quality 
studies -0.28, 95%CI -0.50 – -0.06, I2 53%, P=0.12) and subjects with chronic 
bronchitis (SMD -0.72, 95%CI -1.17 – -0.28, I2 85%, P<0.001; high-quality studies -
0.58, 95%CI -1.08 – -0.08, I2 86%, P<0.001).  
Treatment with erdosteine significantly (P<0.01 to P<0.001) reduced the overall risk 
of chronic bronchitis/COPD exacerbations and the risk of experiencing at least one 
exacerbation vs. control (Figure 3A and B, respectively), with no differences (P>0.05) 
compared to the subset analysis performed by including in the synthesis exclusively 
the studies that enrolled COPD patients (risk of COPD exacerbation: RR 0.74, 
95%CI 0.61 – 0.89, I2 31%, P=0.24; risk of experiencing at least one COPD 
exacerbation: RR 0.78, 95%CI 0.64 – 0.96, I2 6%, P=0.35). In COPD patients 
receiving erdosteine, the time to the first exacerbation was significantly (P<0.001) 
longer than in untreated subjects (Figure 3C). 
Erdosteine also elicited a significant (P<0.05) protective effect on secondary 
endpoints, namely the duration of COPD exacerbation and the risk of hospitalization 
from COPD (Figure 3D and E). 
Bias and quality of evidence 
A significant level of heterogeneity was detected for the overall impact of erdosteine 
on patients suffering from chronic bronchitis and COPD, and the presence of 
publication bias was confirmed by both funnel plot and Egger’s test (Figure 4A and 
B). The subset analysis on COPD did not provide evidence for either heterogeneity, 
or bias related after applying the funnel plot and Egger’s test (Figure 4C and D). 
Although heterogeneity resulted from the forest plot for chronic bronchitis, the funnel 
plot and Egger’s test did not find any evidence for any publication bias (Figure 4E 
and F). Thus, the bias detected that the overall impact on clinical scores was related 
to the concomitant analysis of both chronic bronchitis and COPD. The low level of 
heterogeneity resulting from the meta-analysis of the risk of COPD exacerbation and 
the time to the first exacerbation was further confirmed by funnel plot and Egger’s 
test (Figure 4G to 4J).  
A moderate quality of evidence was detected for the overall clinical impact of 
erdosteine on patients having COPD, and chronic bronchitis, whereas high and low 
quality of evidence resulted from the specific analyses performed on data obtained 
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from patients with COPD and chronic bronchitis, respectively. The GRADE approach 
showed a high quality of evidence for the protective role of erdosteine against the risk 
of COPD exacerbations and on the time of the first exacerbation. Detailed results of 
the GRADE analysis and OIS are reported in Table 2. 
Discussion 
Compared to our previous meta-analysis on erdosteine [10], we have now avoided 
including unpublished data on the recommendation of CRD that the use of 
unpublished data supplied by the manufacturers makes evaluation of potential bias 
difficult [11]. However, while using this more restrictive approach, the current meta-
analysis has confirmed that erdosteine is able to improve clinical score of patients 
with chronic bronchitis and/or COPD. Furthermore, and more importantly, the present 
meta-analysis has documented that erdosteine is also able to reduce the overall risk 
of chronic bronchitis/COPD exacerbations and the risk of experiencing at least one 
exacerbation, lengthen the time to the first COPD exacerbation, reduce the duration 
of COPD exacerbations, and also the risk of hospitalization from COPD. 
The documented effect of erdosteine in preventing and/or influencing COPD 
exacerbations is important because it indicates that erdosteine can be added to the 
list of drugs that can be recommended for the treatment of COPD. The 2017 version 
of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy [34], 
based on the results of two meta-analyses [24, 35] stated that in “in COPD patients 
not receiving inhaled corticosteroids, regular treatment with mucolytics such as 
carbocysteine and N-acetylcysteine (NAC) may reduce exacerbations and modestly 
improve health status”. It also added that currently available data do not allow the 
real target population for mucolytic/antioxidant agents because of the heterogeneity 
of COPD patients enrolled in the studies, doses of treatments, and concomitant 
medications [34]. 
Erdosteine is currently the only mucolytic/antioxidant agent that has been evaluated 
in patients with frequent exacerbations, those that have experienced two or more 
COPD exacerbations requiring medical intervention in the previous 12 months. The 
recent Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in 
COPD (RESTORE) study [13], which enrolled 445 frequent exacerbators, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 10 
demonstrated that erdosteine added on to usual maintenance therapy for COPD 
based on local physician practice and the available guidelines on COPD, reduced the 
exacerbation rate by 19.4% (0.91 versus 1.13 exacerbations/patient−1/year−1 for 
erdosteine and placebo, respectively). Interestingly, no significant differences were 
observed for either the exacerbation rate or duration of exacerbations between those 
patients taking inhaled corticosteroids and those patients not taking inhaled 
corticosteroids. 
In a meta-analysis that we performed before the results of the RESTORE study were 
available erdosteine was within the cluster of the most effective drugs, regardless of 
the level of evidence [36]. However, only N-acetylcysteine 1,200 mg/day significantly 
protected against exacerbations vs. placebo (2 studies analyzed: OR 0.56, 95% CI 
0.35-0.92; p<0.05; high quality of evidence), albeit that this dose was twice the 
recommended dose. The results of the current meta-analysis, which included also 
the RESTORE study, suggest that erdosteine is equally effective to N-acetylcysteine 
in preventing COPD exacerbations, but using the approved dosage regimen. 
We are well aware that meta-analysis provides only the effect estimates that, by 
definition, reflect an estimate of the possible impact of the intervention on the 
investigated outcome(s) and, are in any case, results by indirect comparisons. 
Therefore, we strongly believe that a well-powered RCT that will directly compare the 
efficacy of erdosteine, and N-acetylcysteine is highly desirable. 
Whilst waiting for this comparative pragmatic RCT, the evidence provided from this 
meta-analysis supports the use of erdosteine as add-on therapy to prevent COPD 
exacerbations, especially when administered to patients with frequent exacerbations. 
Conflict of interest 
Mario Cazzola, Luigino Calzetta, and Clive Page are consultants to Recipharm who 
manufacture and market erdosteine. 
References 
1. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev. 
2010;19:127-33. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11 
2. Decramer M, Janssens W. Mucoactive therapy in COPD. Eur Respir Rev. 
2010;19:134-40. 
3. Matera MG, Calzetta L, Cazzola M. Oxidation pathway and exacerbations in 
COPD: the role of NAC. Expert Rev Respir Med. 2016;10:89-97. 
4. Hillas G, Nikolakopoulou S, Hussain S, Vassilakopoulos T. Antioxidants and 
mucolytics in COPD management: when (if ever) and in whom? Curr Drug 
Targets. 2013;14:225-34. 
5. Moretti M. Erdosteine: its relevance in COPD treatment. Expert Opin Drug Metab 
Toxicol. 2009;5:333-43. 
6. Dal Negro RW. Erdosteine: antitussive and anti-inflammatory effects. Lung. 
2008;186:70-3. 
7. Dal Negro RW, Visconti M, Tognella S, Micheletto C. Erdosteine affects 
eicosanoid production in COPD. Int J Clin Pharmacol Ther. 2011;49: 41-5. 
8. Dal Negro RW, Visconti M. Erdosteine reduces the exercise-induced oxidative 
stress in patients with severe COPD: Results of a placebo-controlled trial. Pulm 
Pharmacol Ther. 2016;41:48-51. 
9. Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive 
pulmonary disease. Expert Rev Respir Med. 2007;1:307-16. 
10. Cazzola M, Floriani I, Page CP. The therapeutic efficacy of erdosteine in the 
treatment of chronic obstructive bronchitis: a meta-analysis of individual patient 
data. Pulm Pharmacol Ther. 2010;23:135-44. 
11. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews 
[Internet]. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0029749/. 
12. Moretti M, Fagnani S. Erdosteine reduces inflammation and time to first 
exacerbation postdischarge in hospitalized patients with AECOPD. Int J Chron 
Obstruct Pulmon Dis. 2015;10:2319-25. 
13. Dal Negro RW, Wedzicha JA, Iversen M, Fontana G, Page C, Cicero AF, et al. 
Effect of erdosteine on the rate and duration of COPD exacerbations: the 
RESTORE study. Eur Respir J. 2017;50:1700711. 
14. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items 
for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 
2009;3:e123-30. 
15. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. 
Preferred reporting items for systematic review and meta-analysis protocols 
(PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. 
16. Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib 
and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A 
systematic review and meta-analysis. Pulm Pharmacol Ther. 2016;40:95-103. 
17. Rahman I. Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis. 
2008;2:351-74. 
18. Rahman I. Pharmacological antioxidant strategies as therapeutic interventions for 
COPD. Biochim Biophys Acta. 2012;1822:714-28. 
19. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic 
bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst 
Rev. 2015;CD001287. 
20. Calzetta L, Rogliani P, Matera MG, Cazzola M. A Systematic Review With Meta-
Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable 
COPD. Chest. 2016;149:1181-96. 
21. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The 
number of patients and events required to limit the risk of overestimation of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 12 
intervention effects in meta-analysis--a simulation study. PLoS One. 
2011;6:e25491. 
22. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. 
GRADE guidelines 6. Rating the quality of evidence - imprecision. J Clin 
Epidemiol. 2011;64:1283-93. 
23. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE 
guidelines: 1. Introduction-GRADE evidence profiles and summary of findings 
tables. J Clin Epidemiol. 2011;64:383-94. 
24. Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, et al. 
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a 
meta-analysis. Eur Respir Rev. 2015;24:451-61. 
25. Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the 
gap between methodologists and end-users: R as a computational back-end. J 
Stat Softw. 2012;49:1-15. 
26. Aubier M, Berdah L. [Multicenter, controlled, double-blind study of the efficacy 
and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized 
chronic bronchitis with hypersecretion]. Rev Mal Respir. 1999;16:521-8. 
27. Marchioni CF, Polu JM, Taytard A, Hanard T, Noseda G, Mancini C. Evaluation 
of efficacy and safety of erdosteine in patients affected by chronic bronchitis 
during an infective exacerbation phase and receiving amoxycillin as basic 
treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine 
Study). Int J Clin Pharmacol Ther. 1995;33:612-8. 
28. Bisetti A, Mancini C. Mucolytic activity of erdosteine: double blind clinical trial vs. 
placebo. Arch Med Interna. 1995;47:89-97. 
29. Hotzinger H. Erdosteine or placebo combined with co-trimoxazole in the 
treatment of hypersecretive infectious bronchitis: a double blind clinical trial. Med 
Praxis. 1991;12:171-81. 
30. Ricevuti G, Mazzone A, Uccelli E, Gazzani G, Fregnan GB. Influence of 
erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients 
with an infective exacerbation of chronic bronchitis. Thorax. 1988;43:585-90. 
31. Fioretti M, Bandera M. Prevention of exacerbations in chronic bronchitic patients 
with erdosteine. Med Praxis. 1991;12:219-27. 
32. Moretti M, Bottrighi P, Dallari R, Da Porto R, Dolcetti A, Grandi P, et al. The 
effect of long-term treatment with erdosteine on chronic obstructive pulmonary 
disease: the EQUALIFE Study. Drugs Exp Clin Res. 2004;30:143-52. 
33. de Castro Pereira CA, Cardoso AP, Cavallazzi AC, Pinheiro VGF, de Oliveira 
MVC, Esposito C. Eficácia e tolerabilidade da erdosteína na doença pulmonar 
obstrutiva crônica. Rev Bras Med. 2000;57:481-85. 
34. GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy 
for Diagnosis,Management, and Prevention of COPD – 2017. Available at: 
http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-
copd/. (accessed October 13, 2017). 
35. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic 
bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst 
Rev. 2015;(7):CD001287. 
36. Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG. Impact of mucolytic 
agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 
2017;14:552-63.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 13 
Tables 
Table 1. Patient demographics, baseline and study characteristics. 
Study, year 
and reference 
Trial 
Number 
Identifie
r 
Study characteristics 
Study 
duratio
n 
(weeks) 
Analysed 
patients 
Drug, dose, 
duration of 
treatment 
Disease characteristics Definition of exacerbation  
Age 
(years) 
Male 
(%) 
Current 
smoker
s (%) 
Smokin
g 
history 
(pack-
years) 
Post-
bronc
hodil
ator 
FEV1 
(% 
predi
cted) 
Acute 
exacer
bation
s in 
previo
us 
year 
Clini
cal 
scor
e 
Jada
d 
scor
e 
Dal Negro et al., 
2017 [13] 
NCT 
NCT010
32304; 
RESTO
RE 
Multicentre, randomized, 
double-blind, placebo-
controlled, parallel-group 
52 445 
Erdosteine 300 
mg b.i.d., total 
daily dose 600 
mg, 52 weeks 
Stable COPD (Stage II 
and III according to 
GOLD 2007) as follows: 
post-bronchodilator 
FEV1/FVC<70% 
30%≤FEV1≤70% 
predicted (and at least 
0.7 L absolute value) 
“A symptomatic worsening beyond 
normal day-to-day variations and 
requiring a change in regular 
medication and/or health care 
resources utilisation (e.g. 
increased use of bronchodilators, 
treatment with antibiotics and/or 
systemic corticosteroids, visit to an 
emergency department, 
hospitalization) 
64.8 73.9 28.8 >10 51.8 ≥2 
SGA
DS, 
PGA
DS 
5 
Moretti and 
Fagnani, 2015 
[12] 
NA 
Single-centre, randomized, 
controlled, single-blind 
8 40 
Erdosteine 300 
mg t.i.d., total 
daily dose 900 
mg, 1.4 weeks 
Acute exacerbation of 
COPD 
“Exacerbations … omissis … were 
assessed if changes in therapy 
with antibiotics and/or oral steroids 
were required" 
70.6 82.5 12.5 51.2 47.5 1.3 BCS 3 
Moretti et al., 
2004 [32] 
EQUALI
FE 
Multicentre, randomized, 
double-blind, placebo-
controlled, parallel-group 
32 124 
Erdosteine 300 
mg b.i.d., total 
daily dose 600 
mg, 32 weeks 
Stable COPD (FEV1 
<70%) 
“New episodes of acute disease 
with muco-purulent or purulent 
sputum, cough and at least two of 
the following symptoms: general 
malaise, fever >38 °C, 
breathlessness, difficulty in 
expectoration and leukocytosis.” 
67.5 79.9 32.9 >20 59.2 NA NA 3 
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De Castro 
Pereira et al., 
2000 [33] 
 
NA 
Open label, non 
comparative 
2 38 
Erdosteine 350 
mg b.i.d., total 
daily dose 700 
mg, 2 weeks 
COPD (FEV1/FVC at 
least 10% below normal 
theoretical value) and 
chronic bronchitis (cough 
with expectoration 
occurring for at least 
three months per year , 
for two consecutive 
years with sputum 
volume 30 ml / 24 h) 
“Increased volume and purulence 
of sputum, and worsening of 
dyspnea” # 
62.0 60.0 NA NA 58.0 NA 
NSC
S 
1 
Aubier et al., 
1999 [26] NA 
Multicentre, randomized, 
double-blind, placebo-
controlled, parallel-group 
3 170 
Erdosteine 300 
mg b.i.d., total 
daily dose 600 
mg, 3 weeks 
Stable chronic 
obstructive bronchitis 
with hypersecretion 
(FEV1/FVC at least 10% 
below normal theoretical 
value) 
NA 59.0 58.0 NA NA NA NA cGEI 5 
Marchioni et al., 
1995 [27] 
ECOBE
S 
Multicentre, randomized, 
placebo-controlled, double-
blind 
1.2 237 
Erdosteine 300 
mg b.i.d., total 
daily dose 600 
mg, 1.2 weeks 
Acute exacerbation of 
chronic obstructive 
bronchitis (FEV1/FVC at 
least 10% below normal 
theoretical value) 
NA 66.0 76.0 NA NA NA NA cGEI 5 
Bisetti et al., 
1995 [28] NA 
Double-blind, randomized, 
placebo-controlled 
1 27 
Erdosteine 300 
mg b.i.d., total 
daily dose 600 
mg, 1 week 
Acute exacerbation of 
chronic bronchitis 
NA 62.0 68.0 NA NA NA NA cGEI 5 
Fioretti and 
Bandera, 1991 
[31] 
NA 
Double-blind, randomized, 
placebo-controlled 
26 132 
Erdosteine 300 
mg b.i.d., total 
daily dose 600 
mg, 26 week 
Chronic bronchitis NA 54.8 71.7 NA NA NA NA NA 3 
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Hotzinger et al., 
1991 [29] NA 
Double blind, randomized, 
placebo-controlled 
NA 40 
Erdosteine 300 
mg t.i.d., total 
daily dose 900 
mg 
Hypersecretory infective 
bronchitis (acute 
bronchitis or relapses of 
chronic bronchitis) 
NA 49.0 75.0 NA NA NA NA cGEI 4 
Ricevuti et al., 
1988 [30] NA 
Double blind, placebo-
controlled 
1 24 
Erdosteine 300 
mg t.i.d., total 
daily dose 900 
mg, 1 week 
Acute infective 
exacerbation of chronic 
bronchitis 
NA 57.0 42.0 100.0 
Heavy 
smokers 
(> 20 
cigarette
s/day) 
NA NA cGEI 2 
# Translated from Portuguese 
BCS: breathlessness–sputum–cough scale 
b.i.d.: twice daily 
cGEI: cumulative Global Efficacy Index 
COPD: chronic obstructive pulmonary disease 
FEV1: forced expiratory volume in 1 second 
FVC: Forced vital capacity 
NA: not available 
PGADS: Physician’s Global Assessment of Disease Severity 
SGADS: Subject’s Global Assessment of Disease Severity 
t.i.d.: three times daily 
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Table 1. GRADE evidence profile. 
Outcome 
Quality assessment: erdosteine compared to control in COPD and 
chronic bronchitis 
Quality 
Risk of 
bias Inconsistency Indirectness Imprecision Other considerations 
Overall clinical 
impact on both 
COPD and chronic 
bronchitis 
Not 
serious Serious 
a
 Not serious Not serious b
 
Publication bias 
strongly suspected. 
All plausible residual 
confounding would 
suggest spurious 
effect. c 
⨁⨁⨁◯ 
MODERATE 
Clinical impact on 
COPD 
Not 
serious Not serious Not serious Serious 
d
 
All plausible residual 
confounding would 
suggest spurious 
effect. 
⨁⨁⨁⨁ 
HIGH 
Clinical impact on 
chronic bronchitis 
Not 
serious Serious 
e
 Not serious Serious f None ⨁⨁◯◯ LOW 
Risk of COPD 
exacerbations 
Not 
serious Not serious Not serious 
Not serious 
g
 
None ⨁⨁⨁⨁ HIGH 
Time to the first 
COPD exacerbation 
Not 
serious Not serious Not serious 
Not serious 
h
 
None ⨁⨁⨁⨁ HIGH 
GRADE Working Group grades of evidence 
High quality: we are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, 
but there is a possibility that it is substantially different. 
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the 
effect. 
Very low quality: we have very little confidence in the effect estimate, the true effect is likely to be substantially different from the 
estimate of effect. 
Explanations 
a. I2=82%, P<0.001  
b. Available sample size 7.06% greater that OIS  
c. Confirmed by funnel plot and Egger's test  
d. Available sample size 57.22% smaller that OIS  
e. I2=86%, P<0.001  
f. Available sample size 65.88% smaller that OIS  
g. Available sample size 122.04% greater that OIS  
h. Available sample size 335.00% greater that OIS  
COPD: cronic obstructive pulmonary disease; OIS: optimal information size 
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Figures 
  
Figure 1. PRISMA flow diagram for the identification of studies included in the 
meta-analysis concerning the impact of erdosteine on clinical condition and 
exacerbation rate in patients with chronic bronchitis and/or COPD. 
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Figure 2. Overall forest plot of the impact of erdosteine vs. control on clinical score of patients with chronic bronchitis and COPD 
(A), and subset analysis performed on COPD or chronic bronchitis (B). **P<0.01 and ***P<0.001 vs. control. BCS: breathlessness–
sputum–cough scale; CB: chronic bronchitis; CGEI: cumulative Global Efficacy Index; COPD: chronic obstructive pulmonary 
disease; NSCS: non-specific clinical score; PGADS: Physician’s Global Assessment of Disease Severity; SGADS: Subject’s Global 
Assessment of Disease Severity.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 19
 
Figure 3. Forest plot of the protective effect of erdosteine vs. control on the 
risk of chronic bronchitis/COPD exacerbations (A), the risk of experiencing at 
least one chronic bronchitis/COPD exacerbation (B), the time to the first 
COPD exacerbation (C), the duration of COPD exacerbation (D), and the risk 
of hospitalization for COPD (E). *P<0.05, **P<0.01, and ***P<0.001 vs. 
control.  
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Figure 4. Publication bias assessment via funnel plots (left panels) and Egger’s 
test (right panels) for the impact of erdosteine vs. control on clinical score 
resulting from the concomitant analysis of both COPD and chronic bronchitis 
(A and B), and subset analysis performed in patients affected by COPD (C 
and D) or chronic bronchitis (E and F). The analysis of publication bias 
concerning the risk of COPD exacerbation is reported in G and H, and that 
regarding the time to the first exacerbation is shown in I and J. COPD: chronic 
obstructive pulmonary disease; SND: standard normal deviate. *P<0.1. 
